Sam Altman Stares Into a Bright Light Every Morning and Fasts 15 Hours a Day. Here’s Why – Bitcoin News

Sam Altman’s mornings start with a full spectrum LED light pointed at his face while he works through email, a ritual he once called “It’s a ridiculous gain for me.” The OpenAI CEO also typically fasts for about 15 hours a day, rarely eating breakfast beyond a large shot of espresso, and he takes the diabetes drug metformin, according to a BBC Science Focus Magazine comment piece. The science on metformin as a longevity tool is still unsettled, with the BBC noting there is no solid evidence either way and a 2021 critical review in Frontiers in Endocrinology calling the lifespan case in humans “controversial.” Still, the habits fit neatly into a broader billionaire longevity push, even as Altman has put roughly $180 million into Retro Biosciences and peers like Jeff Bezos back outfits such as Altos Labs.

For all the talk about model roadmaps and compute budgets, some of the most revealing details in Silicon Valley are stubbornly human. A 2026 comment piece from BBC Science Focus Magazine pulled back the curtain on a slice of Sam Altman’s day that feels both oddly mundane and intensely optimized, down to the light he stares at and the hours he spends not eating.

Sam Altman’s unconventional morning routine

Most mornings, the OpenAI CEO starts with email, but not in the usual half-awake scroll. He sits under a full-spectrum LED light for about 10 to 15 minutes while catching up, a habit he credited as “It’s a ridiculous gain for me.” on his own productivity blog post.

He also tries to protect that early window. Altman has written that he avoids scheduling early meetings because that is when he is most productive, a small tell about how a leader in the AI arms race manages attention before the day’s requests pile up.

The 15-hour fast, plus a pharmaceutical side quest

Altman’s mornings are caffeinated and sparse. In a 2018 blog post, he wrote that he drinks a large shot of espresso immediately after waking up, and that he rarely eats breakfast, which typically pushes him into a 15-hour daily fast.

Then there’s the medication: Altman takes metformin, a diabetes drug, as part of his longevity experimentation, per the BBC Science Focus piece. The same comment piece is blunt that there is currently no solid evidence either way on whether this will help him live longer, which neatly captures the gap between personal conviction and clinical proof.

What the science says, and what it doesn’t

Metformin has attracted serious scientific attention, but the signal remains mixed. A peer-reviewed 2021 critical review in Frontiers in Endocrinology concluded that while some data is supportive, the evidence that metformin increases lifespan in humans “remains controversial.”

Researchers are trying to tighten that uncertainty into something measurable. Clinical trials including MILES (Metformin In Longevity Study) and TAME (Targeting Aging with Metformin) have been designed specifically to test metformin’s potential anti-aging effects in humans.

From biohacking to big checks

Altman isn’t only dabbling at the personal level. He has personally funded Retro Biosciences, a longevity biotech pursuing cellular reprogramming and plasma-based interventions aimed at extending healthy human lifespan, and Outlook Business puts his investment at roughly $180 million.

He’s part of a broader pattern among tech leaders: Amazon founder Jeff Bezos backs Altos Labs, another company working on cellular rejuvenation. The BBC Science Focus critique is that billionaires could potentially help reverse aging for everyone, yet much of the momentum still clusters around private routines and privately funded bets.